INmune Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2016
Revenue	0.16	0.37	0.18	0.01	0	Upgrade
Revenue Growth (YoY)	-58.56%	106.63%	1545.45%	-	-	Upgrade
Gross Profit	0.16	0.37	0.18	0.01	0	Upgrade
Selling, General & Admin	9.62	9.26	8.79	6.32	6.02	Upgrade
Research & Development	20.27	17.07	20.54	5.92	3.28	Upgrade
Other Operating Expenses	0.27	1.35	1.19	0	-1.54	Upgrade
Operating Expenses	30.16	27.67	30.52	12.24	7.76	Upgrade
Operating Income	-30.01	-27.3	-30.34	-12.23	-7.76	Upgrade
Other Expense / Income	-	-	-	-0.13	-0.08	Upgrade
Pretax Income	-30.01	-27.3	-30.34	-12.1	-7.68	Upgrade
Net Income	-30.01	-27.3	-30.34	-12.1	-7.68	Upgrade
Shares Outstanding (Basic)	18	18	16	12	10	Upgrade
Shares Outstanding (Diluted)	18	18	16	12	10	Upgrade
Shares Change	0.30%	11.14%	34.55%	16.70%	18.39%	Upgrade
EPS (Basic)	-1.67	-1.52	-1.88	-1.01	-0.75	Upgrade
EPS (Diluted)	-1.67	-1.52	-1.88	-1.01	-0.75	Upgrade
Free Cash Flow	-11.98	-22.69	-28.5	-8.94	-5.38	Upgrade
Free Cash Flow Per Share	-0.67	-1.26	-1.77	-0.75	-0.52	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	Upgrade
Operating Margin	-19360.00%	-7299.20%	-16762.43%	-111163.64%	-	Upgrade
Profit Margin	-19360.00%	-7299.20%	-16762.43%	-109990.91%	-	Upgrade
Free Cash Flow Margin	-7729.03%	-6065.78%	-15748.07%	-81300.00%	-	Upgrade
EBITDA	-30.01	-27.3	-30.34	-12.1	-7.68	Upgrade
EBITDA Margin	-19360.00%	-7299.20%	-16762.43%	-109990.91%	-	Upgrade
EBIT	-30.01	-27.3	-30.34	-12.1	-7.68	Upgrade
EBIT Margin	-19360.00%	-7299.20%	-16762.43%	-109990.91%	-	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).